Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
12
×
Tags
boston blog main
boston top stories
detroit blog main
detroit top stories
12
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
12
×
raleigh-durham blog main
raleigh-durham top stories
12
×
roche
12
×
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
national
biotech
cancer
indiana blog main
indiana top stories
pfizer
clinical trials
deals
fda
merck
startups
amgen
immunotherapy
investing
vertex pharmaceuticals
bristol-myers squibb
What
roundup
bio
drug
annual
cancer
society
clinical
conference
crispr
medical
oncology
today
ahead
american
asco
ash
big
ceo
companies
days
esmo
european
fda
latest
medicine
meeting
new
patients
plan
time
acquisitions
admits
advantages
ago
albert
alliance
alzheimer’s
ambien
approved
attendees
Language
unset
unknown
Current search:
roche
×
photo
×
" raleigh-durham top stories "
×
" new york top stories "
×
" detroit top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More